{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T11:09:25Z","timestamp":1794568165819,"version":"4.9.1"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T00:00:00Z","timestamp":1657756800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The dual COVID-19 and overdose emergencies amplified strain on healthcare systems tasked with responding to both. One downstream consequence of the pandemic in the USA and Canada was a surge in drug overdoses resulting from public health-restricted access to services and an increasingly toxic unregulated drug supply. This study aimed to describe changes implemented by programs prescribing pharmaceutical alternatives to the drug supply during the early stages of the COVID-19 pandemic.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>An environmental scan used surveys and qualitative interviews with service providers across Canada to examine pharmaceutical alternative prescribing practices and programs before and during the pandemic. This study summarized the nature, frequency, and reasons for pandemic-driven service delivery changes using directed content analysis, counts, and thematic analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Eighty-two of the 103 participating sites reported 1193 unique changes in physical space (368), client protocols (347), program operations (342), ancillary services (127), and staffing (90). Four qualitative themes describing the reasons for these changes emerged, namely (1) decreasing risk of COVID-19 infection; (2) decreasing risk of overdose; (3) prioritizing acute care of COVID-19 patients; and (4) improving client access to treatment.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>While most changes were aimed at decreasing risk of COVID-19 infection, some were found to be at odds with the measures needed to combat the overdose crisis; others met dual objectives of decreased risk of both overdose and infection. Further research should examine which changes should be kept or reversed once COVID-19-related public health measures are lifted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12954-022-00657-x","type":"journal-article","created":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:05:14Z","timestamp":1657800314000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["The changing landscape of pharmaceutical alternatives to the unregulated drug supply during COVID-19"],"prefix":"10.1186","volume":"19","author":[{"given":"Karen","family":"McCrae","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Glegg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-\u00c9ve","family":"Goyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Le Foll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rupi","family":"Brar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Sutherland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4195-3284","authenticated-orcid":false,"given":"Nadia","family":"Fairbairn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,7,14]]},"reference":[{"key":"657_CR1","unstructured":"Ahmad F, Rossen L, Sutton P. Provisional drug overdose death counts. National Center for Health Statistics; 2021. https:\/\/www.cdc.gov\/nchs\/nvss\/vsrr\/drug-overdose-data.htm."},{"key":"657_CR2","unstructured":"Special Advisory Committee on the Epidemic of Opioid Overdoses. Opioid and Stimulant-related Harms in Canada. Ottawa: Public Health Agency of Canada; 2021. https:\/\/health-infobase.canada.ca\/src\/doc\/SRHD\/UpdateDeathsSep2021.pdf."},{"key":"657_CR3","unstructured":"Health Canada. Government of Canada helping expand access to safer supply across Canada. 2021. https:\/\/www.canada.ca\/en\/health-canada\/news\/2021\/06\/government-of-canada-helping-expand-access-to-safer-supply-across-canada.html."},{"key":"657_CR4","first-page":"25","volume-title":"Risk mitigation in the context of dual health emergencies v1.5","author":"K Ahamad","year":"2020","unstructured":"Ahamad K, Bach P, Brar R, Chow N, Coll N, Compton M, et al. Risk mitigation in the context of dual health emergencies v1.5. Vancouver: British Columbia Centre on Substance Use; 2020. p. 25."},{"key":"657_CR5","unstructured":"Brar R, Bruneau J, Goyer M, Lim R, Poulin G, Sereda A, et al. Medications and other clinical approaches to support physical distancing for people who use substances during the COVID-19 pandemic: National Rapid Guidance Document. Vancouver: CRISM; 2020. https:\/\/crism.ca\/wp-content\/uploads\/2020\/06\/CRISM-Guidance-Medications-and-other-clinical-approaches-22062020-final.pdf."},{"key":"657_CR6","unstructured":"Hales J, Kolla G, Man T, O\u2019Reilly E, Rai N, Sereda A. Safer opioid supply programs (SOS): a harm reduction informed guiding document for primary care teams-April 2020 update. 2019. https:\/\/bit.ly\/3dR3b8m."},{"key":"657_CR7","unstructured":"Goyer ME, Hudon K, Plessis-B\u00e9lair MC, Ferguson Y. Substance replacement therapy in the context of the COVID-19 pandemic in Qu\u00e9bec: clinical guidance for prescribers. Montr\u00e9al: IUD; 2020. http:\/\/dependanceitinerance.ca\/wp-content\/uploads\/2020\/10\/Guide-Pharmaco-COVID_ANG-VF.19.10.20.pdf."},{"issue":"1","key":"657_CR8","doi-asserted-by":"publisher","first-page":"E115","DOI":"10.9778\/cmajo.20200021","volume":"9","author":"E Eydt","year":"2021","unstructured":"Eydt E, Glegg S, Sutherland C, Meador K, Trew M, Perreault M, et al. Service delivery models for injectable opioid agonist treatment in Canada: 2 sequential environmental scans. CMAJ Open. 2021;9(1):E115\u201324.","journal-title":"CMAJ Open"},{"key":"657_CR9","doi-asserted-by":"crossref","unstructured":"Weng J, Fairbairn N, Sutherland C, Johnson C, Nolan S. Supervised tablet injectable opioid agonist therapy (TiOAT): a strategy to address safer supply for individuals with an opioid use disorder? J Addict Me. 2022. http:\/\/journals.lww.com\/journaladdictionmedicine\/Abstract\/9000\/Supervised_Tablet_Injectable_Opioid_Agonist.99020.aspx.","DOI":"10.1097\/ADM.0000000000000887"},{"issue":"106","key":"657_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2022.103742","volume":"6","author":"S Glegg","year":"2022","unstructured":"Glegg S, McCrae K, Kolla G, Touesnard N, Turnbull J, Brothers TD, et al. \u201cCOVID just kind of opened a can of whoop-ass\u201d: the rapid growth of safer supply prescribing during the pandemic documented through an environmental scan of addiction and harm reduction services in Canada. Int J Drug Policy. 2022;6(106): 103742.","journal-title":"Int J Drug Policy"},{"key":"657_CR11","unstructured":"Canadian Research Initiative in Substance Misuse (CRISM). National injectable opioid agonist treatment for opioid use disorder operational guidance. 2019. https:\/\/crism.ca\/projects\/ioat-guideline\/."},{"key":"657_CR12","unstructured":"Health Canada. Safer supply: prescribed medications as a safer alternative to toxic illegal drugs. 2021. https:\/\/www.canada.ca\/en\/health-canada\/services\/opioids\/responding-canada-opioid-crisis\/safer-supply.html."},{"key":"657_CR13","doi-asserted-by":"publisher","DOI":"10.5812\/sdme.67670","author":"M Naderifar","year":"2017","unstructured":"Naderifar M, Goli H, Ghaljaie F. Snowball sampling: a purposeful method of sampling in qualitative research. Strides Dev Med Educ. 2017. https:\/\/doi.org\/10.5812\/sdme.67670.","journal-title":"Strides Dev Med Educ"},{"key":"657_CR14","unstructured":"NVivo 12.6.1. 2021."},{"key":"657_CR15","doi-asserted-by":"publisher","DOI":"10.1177\/1049732305276687","author":"H Hsieh","year":"2005","unstructured":"Hsieh H, Shannon S. Three approaches to qualitative content analysis. Qual Health Res. 2005. https:\/\/doi.org\/10.1177\/1049732305276687.","journal-title":"Qual Health Res"},{"issue":"1","key":"657_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/1609406917733847","volume":"16","author":"L Nowell","year":"2017","unstructured":"Nowell L, Norris J, White D, Moules N. Thematic analysis: striving to meet the trustworthiness criteria. Int J Qual Methods. 2017;16(1):1\u201313.","journal-title":"Int J Qual Methods"},{"key":"657_CR17","first-page":"198","volume-title":"The coding manual for qualitative researchers","author":"J Saldana","year":"2016","unstructured":"Saldana J. First cycle coding methods. In: Seaman J, editor. The coding manual for qualitative researchers. 3rd ed. Los Angeles: SAGE Publications, Inc.; 2016. p. 198\u2013204.","edition":"3"},{"key":"657_CR18","unstructured":"Lovgreen T, Smyth G. Where to go? What happens when nature calls during a pandemic | CBC News. CBC; 2020. https:\/\/www.cbc.ca\/news\/canada\/british-columbia\/where-to-go-what-happens-when-nature-calls-during-a-pandemic-1.5610802."},{"key":"657_CR19","unstructured":"CPBC. Professional Practice Policy #66 Policy Guide Slow Release Oral Morphine (SROM) maintenance treatment. 2018. http:\/\/library.bcpharmacists.org\/6_Resources\/6-2_PPP\/1047-PPP66_Policy_Guide_SROM.pdf."},{"key":"657_CR20","unstructured":"Post-mortem detection of hydromorphone among persons identified as having an illicit drug toxicity death since the introduction of Risk Mitigation Guidance prescribing. BC Centre for Disease Control; 2021. http:\/\/www.bccdc.ca\/resource-gallery\/Documents\/Statistics%20and%20Research\/Statistics%20and%20Reports\/Overdose\/2021.09.15_Knowledge%20Update_Hydromorphone%20and%20drug%20toxicity%20deaths.pdf."}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-022-00657-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-022-00657-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T12:14:23Z","timestamp":1657800863000},"score":1,"resource":{"primary":{"URL":"https:\/\/harmreductionjournal.biomedcentral.com\/articles\/10.1186\/s12954-022-00657-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,14]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["657"],"URL":"https:\/\/doi.org\/10.1186\/s12954-022-00657-x","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,14]]},"assertion":[{"value":"27 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the University of British Columbia\/Providence Health Care Research Ethics Board (H17-01794) and with the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors certify that the enclosed manuscript is not being considered for publication elsewhere; all authors have reviewed and approved the manuscript for submission for publication.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Dr. Le Foll has obtained funding from Pfizer (GRAND Awards, including salary support) for investigator-initiated projects. Dr. Le Foll has some in-kind donation of cannabis product from Aurora and medication donation from Pfizer and Bioprojet and was provided a coil for TMS study from Brainsway. Dr. Le Foll has obtained industry funding from Canopy (through research grants handled by Centre for Addiction and Mental Health [CAMH] or University of Toronto), Bioprojet, American Chemical Society (ACS) and Alkermes. Dr. Le Foll has received in-kind donations of nabiximols from GW Pharma for past studies funded by CIHR and the National Institutes for Health (NIH). He has been consultant for Shionogi. No other authors have relevant financial or non-financial interests to disclose.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"77"}}